Please assess the completion status of the following clinical trial:

Trial Title: Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of one of the following hematopoietic malignancies:~  * Acute lymphoblastic leukemia or myeloid leukemia with \< 30% blasts in the bone marrow~ * Juvenile myelomonocytic leukemia~ * Chronic myelogenous leukemia in chronic or accelerated phase~ * Relapsed non-Hodgkin's or Hodgkin's lymphoma in at least partial remission~* Considered at high risk (\> 30%) of toxic death with standard hematopoietic stem cell transplantation (HSCT), as indicated by at least one of the following:~  * Creatinine \> 1.5 times normal OR creatinine clearance \< 70 mL/min OR tubular damage that is not corrected by cessation of chemotherapy~ * DLCO \< 60% of predicted OR history of prior intubation due to lung disease (intubation for surgery excluded)~ * Shortening fraction \< 30%~ * History of disseminated fungal infection during chemotherapy OR currently receiving antifungal agents OR history of ≥ 2 septic episodes (confirmed by cultures) that required ICU support~    * Patients with improving fungal or other infections eligible~      * Improving infection is defined as confirmed negative cultures on 2 separate occasions, at least 1 week apart, and/or stable or improving imaging studies (e.g., CT scan) of the infected site~     * Two imaging studies taken at least 2 weeks apart must show stable or improved disease~ * History of stroke or abnormal MRI/MRA OR leukoencephalopathy OR seizures that are not fully controlled with anticonvulsants (\> 2 episodes of seizures in the preceding year or 1 episode of status epilepticus in a patient who is receiving anticonvulsant therapy)~ * History of prior significant bleeding (e.g., pulmonary, CNS, or gastrointestinal) OR history of a clotting disorder as manifested by prior significant thromboses (e.g., superior vena cava, inferior vena cava, or femoral vein)~* Failed conventional therapies and not eligible for myeloablative protocols~  * May have failed prior conventional HSCT~* No active CNS leukemia~* Unrelated or related donor available, meeting the following criteria:~  * Matched for at least 7/8 loci by high-resolution typing~ * One mismatch at A, B, or C loci allowed~ * Fully matched at DRB1 locus~PATIENT CHARACTERISTICS:~* ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%~* No active/progressing viral, bacterial, protozoal, or fungal infection~* Transaminases ≤ 5 times normal (except in the presence of autoimmune liver disease)~* Shortening fraction ≥ 25%~* DLCO ≥ 40% OR pulse oximetry ≥ 85% on room air~* Glomerular filtration rate ≥ 40 mL/min~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Prior prolonged intensive chemotherapy (\> 3 years of therapy or ≥ 3 different chemotherapeutic protocols) allowed

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy